Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 839

1.

HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.

Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Cancer Biol Ther. 2011 Nov 1;12(9):837-45. doi: 10.4161/cbt.12.9.17713. Epub 2011 Nov 1.

PMID:
21885917
2.

HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells.

Tierney BJ, McCann GA, Cohn DE, Eisenhauer E, Sudhakar M, Kuppusamy P, Hideg K, Selvendiran K.

Cancer Biol Ther. 2012 Jul;13(9):766-75. doi: 10.4161/cbt.20559.

PMID:
22801507
3.

Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts.

Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, Ravi Y, Trigg NJ, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Mol Cancer Ther. 2010 May;9(5):1169-79. doi: 10.1158/1535-7163.MCT-09-1207. Epub 2010 May 4.

4.

NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.

Bratasz A, Selvendiran K, Wasowicz T, Bobko A, Khramtsov VV, Ignarro LJ, Kuppusamy P.

J Transl Med. 2008 Feb 26;6:9. doi: 10.1186/1479-5876-6-9.

5.

Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma.

Lau CK, Yang ZF, Lam SP, Lam CT, Ngai P, Tam KH, Poon RT, Fan ST.

Cancer Biol Ther. 2007 Dec;6(12):1900-7. Epub 2007 Sep 1.

PMID:
18059167
6.

Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.

Yang YI, Kim JH, Lee KT, Choi JH.

Gynecol Oncol. 2011 Dec;123(3):588-96. doi: 10.1016/j.ygyno.2011.08.031. Epub 2011 Sep 25.

PMID:
21945308
7.
8.

Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin.

Liu T, Peng H, Zhang M, Deng Y, Wu Z.

Eur J Pharmacol. 2010 Sep 1;641(1):15-22. doi: 10.1016/j.ejphar.2010.04.062. Epub 2010 May 17.

PMID:
20483353
9.

Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells.

Montopoli M, Ragazzi E, Froldi G, Caparrotta L.

Cell Prolif. 2009 Apr;42(2):195-206. doi: 10.1111/j.1365-2184.2009.00585.x. Epub 2009 Feb 18.

PMID:
19236381
10.

The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.

Yuan Z, Cao K, Lin C, Li L, Liu HY, Zhao XY, Liu L, Deng HX, Li J, Nie CL, Wei YQ.

Mol Med. 2011;17(11-12):1262-74. doi: 10.2119/molmed.2011.00176. Epub 2011 Aug 19.

11.

Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog.

Abuzeid WM, Davis S, Tang AL, Saunders L, Brenner JC, Lin J, Fuchs JR, Light E, Bradford CR, Prince ME, Carey TE.

Arch Otolaryngol Head Neck Surg. 2011 May;137(5):499-507. doi: 10.1001/archoto.2011.63.

12.

P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.

Joshi KS, Rathos MJ, Mahajan P, Wagh V, Shenoy S, Bhatia D, Chile S, Sivakumar M, Maier A, Fiebig HH, Sharma S.

Mol Cancer Ther. 2007 Mar;6(3):926-34.

13.

RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.

Liu M, Qi Z, Liu B, Ren Y, Li H, Yang G, Zhang Q.

Oncotarget. 2015 Sep 22;6(28):25281-94. doi: 10.18632/oncotarget.4634.

14.

Oxygenation inhibits ovarian tumor growth by downregulating STAT3 and cyclin-D1 expressions.

Selvendiran K, Kuppusamy ML, Ahmed S, Bratasz A, Meenakshisundaram G, Rivera BK, Khan M, Kuppusamy P.

Cancer Biol Ther. 2010 Aug 15;10(4):386-90. Epub 2010 Aug 21.

PMID:
20562529
15.

VEGF antibody plus cisplatin reduces angiogenesis and tumor growth in a xenograft model of ovarian cancer.

Ghosh S, Maity P.

J Environ Pathol Toxicol Oncol. 2010;29(1):17-30.

PMID:
20528744
16.
18.

HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer.

Rath KS, Naidu SK, Lata P, Bid HK, Rivera BK, McCann GA, Tierney BJ, Elnaggar AC, Bravo V, Leone G, Houghton P, Hideg K, Kuppusamy P, Cohn DE, Selvendiran K.

Cancer Res. 2014 Apr 15;74(8):2316-27. doi: 10.1158/0008-5472.CAN-13-2433. Epub 2014 Mar 3.

19.

Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells.

Han Z, Feng J, Hong Z, Chen L, Li W, Liao S, Wang X, Ji T, Wang S, Ma D, Chen G, Gao Q.

Biochem Biophys Res Commun. 2013 May 31;435(2):188-94. doi: 10.1016/j.bbrc.2013.04.087. Epub 2013 May 7.

PMID:
23665025
20.

A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer.

Zhang B, Liu Y, Zhang P, Wei Y, Yin X, Zheng J.

Int J Gynecol Cancer. 2011 Dec;21(9):1540-6. doi: 10.1097/IGC.0b013e31823105ed.

PMID:
22080895
Items per page

Supplemental Content

Write to the Help Desk